Here, we first discovered fluphenazine, activates KLF14, inhibits the expression of IRP2, impairs cellular iron metabolism and leads to the suppression of the liver cancer cell growth in vitro and vivo. Our research in HCC cells further suggests its high potential as an anti-tumor agent as an activator of KLF14. Here, KLF14 is linked to hepatocellular carcinoma.